-cAMP-raising agents with glucagon-like peptide-1 (GLP-1) as the first in class, exhibit multiple actions that are beneficial for the treatment of type 2 diabetic (T2D) patients, including improvement of glucose-induced insulin secretion (GIIS). To gain additional insight into the role of cAMP in the disturbed stimulus-secretion coupling within the diabetic ␤-cell, we examined more thoroughly the relationship between changes in islet cAMP concentration and insulin release in the GK/Par rat model of T2D. Basal cAMP content in GK/Par islets was significantly higher, whereas their basal insulin release was not significantly different from that of Wistar (W) islets. Even in the presence of IBMX or GLP-1, their insulin release did not significantly change despite further enhanced cAMP accumulation in both cases. The high basal cAMP level most likely reflects an increased cAMP generation in GK/Par compared with W islets since 1) forskolin dose-dependently induced an exaggerated cAMP accumulation; 2) adenylyl cyclase (AC)2, AC3, and G s␣ proteins were overexpressed; 3) IBMX-activated cAMP accumulation was less efficient and PDE-3B and PDE-1C mRNA were decreased. Moreover, the GK/Par insulin release apparatus appears less sensitive to cAMP, since GK/Par islets released less insulin at submaximal cAMP levels and required five times more cAMP to reach a maximal secretion rate no longer different from W. GLP-1 was able to reactivate GK/Par insulin secretion so that GIIS became indistinguishable from that of W. The exaggerated cAMP production is instrumental, since GLP-1-induced GIIS reactivation was lost in the presence the AC blocker 2=,5=-dideoxyadenosine. This GLP-1 effect takes place in the absence of any improvement of the [Ca 2ϩ ]i response and correlates with activation of the cAMP-dependent PKA-dependent pathway. type 2 diabetes; glucagon-like peptide-1; insulin secretion; cyclic AMP metabolism; cyclic AMP resistance; calcium metabolism IN NORMAL ␤-CELLS, metabolism of glucose leads to an increase in intracellular ATP, which in turn induces the depolarization of the plasma membrane through the closure of ATP-sensitive potassium channels (16). Subsequently, membrane depolarization causes the opening of voltage-dependent calcium channels and elevation of cytosolic calcium (16). The resultant rise in intracellular calcium is required for glucose-induced insulin release (GIIS). This rise is also linked to an increase in the second messenger cAMP (35, 36) . It has long been recognized that cAMP is essential for maintaining primary ␤-cells in a glucose-competent state (39). Furthermore, cAMP has again been in focus during the last couple of years, because incretin hormones released from the gut, such as glucagon-like peptide-1 (GLP-1), which potentiate GIIS, exert their effects via an increase in cellular cAMP (7, 9, 18). It has also been recently proposed that glucose and GLP-1 produce cAMP in ␤-cell lines with distinct kinetics and adenylyl cyclases (22, 34).
IN NORMAL ␤-CELLS, metabolism of glucose leads to an increase in intracellular ATP, which in turn induces the depolarization of the plasma membrane through the closure of ATP-sensitive potassium channels (16) . Subsequently, membrane depolarization causes the opening of voltage-dependent calcium channels and elevation of cytosolic calcium (16) . The resultant rise in intracellular calcium is required for glucose-induced insulin release (GIIS). This rise is also linked to an increase in the second messenger cAMP (35, 36) . It has long been recognized that cAMP is essential for maintaining primary ␤-cells in a glucose-competent state (39) . Furthermore, cAMP has again been in focus during the last couple of years, because incretin hormones released from the gut, such as glucagon-like peptide-1 (GLP-1), which potentiate GIIS, exert their effects via an increase in cellular cAMP (7, 9, 18) . It has also been recently proposed that glucose and GLP-1 produce cAMP in ␤-cell lines with distinct kinetics and adenylyl cyclases (22, 34) .
Type 2 diabetes (T2D) is the most prevalent form of diabetes mellitus. It is now widely accepted that T2D evolves when insulin secretion from the pancreatic ␤-cells fails. As a consequence, enhancement of insulin secretion from the ␤-cell is one of principal goals for treatment of patients with T2D. Whether cAMP metabolism is impaired in islets from patients with T2D is unknown. The information so far available comes only from rodent models of T2D (1, 3) . Deficient glucose-induced cAMP generation has been reported in nSTZ rat islets (3) but not in GK/Sto islets (1), whereas stimulation of adenylyl cyclase (AC) by forskolin elicited an exaggerated insulin secretion at low glucose and restored the GIIS in GK/Sto islets (1) . Overexpression of several AC isoforms was also described in nSTZ rat islets (8) and in both GK/Sto and GK/Par islets (1, 31) , but there is some degree of controversy surrounding cAMP data obtained in the GK models (31) .
To gain additional insight into the role of cAMP in the stimulus-secretion coupling within the diabetic ␤-cell, we examined more thoroughly the relationship between changes in islet cAMP concentration and insulin release in the GK/Par model. The specific aims of the present study were to assess in GK/Par islets 1) basal cAMP production and degradation, 2) the cAMP response to glucose, 3) cAMP effectiveness on the insulin secretory pathway, and 4) whether their GIIS is affected by GLP-1 and the way it is. 9 .8 Ϯ 0.4 (n ϭ 40) (P Ͻ 0.001 compared with W), and 9.2 Ϯ 0.5 mmol/l (n ϭ 30) (P Ͻ 0.001 compared with W), respectively.
Required chemicals and sources. The 125 I-labeled insulin was from DiaSorin and the 125 I-labeled adenosine 3=,5=-cyclic-phosphoric acid-2=-O-succinyl-3 from Amersham. Purified rat insulin was supplied by Novo Research Institute (Copenhagen, Denmark). 2=,5=-Dideoxyadenosine (dd-Ado) and H89 were from Calbiochem. D-Glucose, Tris, and the salts used to make the Hanks' solution and Krebs-Ringer buffer (KRB) were from Merck. Other chemicals were from SigmaAldrich.
Islet isolation. Rats (3-4 mo old) were killed by decapitation. For each islet preparation, three pancreases were digested with collagenase, and the islets were hand picked under a stereomicroscope.
Measurements of islet insulin release during perifusion procedure. Eight freshly isolated islets at a time were allowed to attach on a polylysine-treated cover-glass transferred to a perifusion chamber placed on the stage of an inverted microscope (Nikon, Diaphot, France). Cannulas feeding into the chamber were connected to a peristaltic pump and allowed a continuous perifusion of the islets at a flow rate of 1 ml/min with a 25 mM HEPES-buffered medium maintained at 37°C, containing (in mM) 125 NaCl, 5.9 KCl, 1.28 CaCl 2, 1.2 MgCl2, and 2.8 or 16.7 glucose (G2.8, G16.7), and 1 mg/ml BSA. The perifusion fluid was collected from the chamber at 60-s intervals and stored at Ϫ20°C for insulin radioimmunoassay.
Measurements of islet [Ca 2ϩ ]i. Freshly isolated islets were loaded for 1 h with 5 M fura 2-AM at 37°C in KRB containing (in mM) 115 NaCl, 5 KCl, 24 NaHCO3, 1 CaCl2, 1 MgCl2, and 5.5 glucose, and 5 mg/ml BSA. After loading, eight islets at a time were allowed to attach on a polylysine-treated cover-glass and perifused as described in the previous paragraph. Intracellular free Ca 2ϩ concentration ([Ca 2ϩ ]i) was determined at 20-s intervals as previously described (6) . Measurements of islet cAMP content and insulin release during static incubation. cAMP content was measured in islet pellets, and insulin release was determined in the incubation buffer from the same batches of islets using radioimmunoassays as described previously (3) . Briefly, after a 60-min preincubation period, groups of 20 freshly isolated islets were incubated for 15 or 20 min in 1 ml of KRB-BSA medium containing G2.8 or G16.7 alone or supplemented with IBMX or forskolin as specified. In GLP-1 experiments, all islet samples were incubated with the above-mentioned test substances 10 min before stimulation (t0) with 100 nM GLP-1. Islet cAMP content and insulin release were determined after up to 10 min of incubation.
Islet DNA content. In some experiments, at least two batches of 20 islets from control or GK rats were collected to determine DNA by fluorometric assay as previously described (6) .
Western blotting. Frozen islets were homogenized in a buffer containing 50 mM Tris·HCl (pH7.4), 150 mM NaCl, a protease inhibitor cocktail (Roche-diagnostic, Mannheim, Germany), and centrifuged for 5 min at 1,000 g at 4°C. Protein concentration in the supernatant was determined by BCA protein assay kit (Interchim, Montluçon, France). Protein samples were heated for 10 min at 95°C with Laemmli's buffer and were resolved by SDS-PAGE, with 7.5% (wt/vol) acrylamide. Proteins were then transferred to nitrocellulose (Amersham. Les Ulis, France), and the membranes were blocked as described previously (23) . The following primary antibodies were used: polyclonal anti-AC3 and anti-AC8, anti-Gs␣ (Santa Cruz Biotechnology, dilution 1:500) and anti-MEK1 (Ozyme, St Quentin en Yvelines, France), in 5% nonfat dried milk in TBS (Tris buffered saline: 20 mM Tris·HCl, pH 7.5, 500 mM NaCl). After three washes (10 min each) with TBS, membranes were incubated with appropriate secondary antibodies. The immunoreactive bands were visualized by the ECL detection system (GE Healthcare Europe, Orsay, France). MEK1 protein was used for normalization. Intensities of the respective bands were examined by densitometric analysis (Scion Image Analyst program).
Immunofluorescent staining and confocal microscopy. Islet sections (5 m) were incubated with a mixture of guinea pig antiinsulin and rabbit anti-Gs␣ (Santa Cruz Biotechnology) or guinea pig anti-insulin and rabbit anti-AC2 (Santa Cruz Biotechnology) antibodies overnight at 4°C. Following washes, sections were incubated with a mixture of TRITC-conjugated anti-rabbit IgG (Jackson ImmunoResearch) and FITC-conjugated anti-guinea pig IgG (Jackson ImmunoResearch) for 1 h at room temperature. After washes, sections were mounted in Vectashield mounting medium (Vector, France). Immunofluorescent specimens were examined using an inverted microscope (Leica DM IRE2) fitted with a confocal imaging system (Leica SP2-AOBS). Islet sections were scanned cross-sectionally making serial optical sections of ϳ1-m interval. For fluorescein and TRITC excitations, the system uses an argon/krypton laser. The two images obtained from each excitation can then be merged into a single color image for comparing the distribution of positive immunoreactivity for each antibody.
RNA extraction and cDNA synthesis. Total RNA was isolated from 1,200 pancreatic W or GK islets, using an RNeasy minikit (Qiagen). The concentration of RNA samples was ascertained by measuring optical density at 260 nm. The integrity of RNA was confirmed by the detection of 18S and 28S bands after agarose-formaldehyde gel electrophoresis. The quality of RNA was verified by optical density absorption ratio OD 260 nm/OD 280 nm. To remove residual DNA contamination, the RNA samples were treated with DNAse RNAsefree (Qiagen) and purified with an RNeasy minicolumn (Qiagen). Two micrograms of total RNA from each sample was reverse transcribed with 20 U of M-MLV reverse transcriptase (Invitrogen, Life technologies) using random hexamer primers.
Oligonucleotide primers. The primer sequences used for ADCY1, ADCY2, ADCY3, ADCY8, GTP␣s, PDE-1c, PDE-3b, and housekeeping genes (18S, rpL19, and cyclophilin B) were derived from rat sequences. The primers were as follows: ADCY1 (3=-CCAGCCCAA-GACGGATCA-5=, 5=-GGTGACGTCGTTGGACAATA-3=), ADCY2 (3=-CCGGGACTGGCTCTACGAGT-5=, 5=-GGGCAGTGGGAAC-CGTTATT-3=), ADCY3 (3=-CGGCCATGGTGGAGATACTTA-5=, 5=-CCAAGATGAGAAGGCCACGA-3=), ADCY8 (3=-GCATCAGTTC-CACCGCATCTA-5=, 5=-GGGCCAGCCGATCAAAT-3=), GTP␣s (3=-GGAGAGGGCGGCGAAGA-5=, 5=-GGCAATTCCAGCATG-CAAA-3=), PDE-1c (3=-GGAGGCCCTTGAAGTTGGTTA-5=, 5=-GCCGAGAAGATTATTGCAAAGA-3=), PDE-3b (3=-GCAGTG-GCAAGATGTTCAGGA-5=, 5=-GGGAAGGCTTGGGTCAATCA-3=).
Real-time PCR. Real-time quantitative PCR amplification reactions were carried out in a LightCycler 1.5 detection system (Roche) using the LightCycler FastStart DNA Master plus SYBR Green I kit (Roche). Reverse transcribed RNA (20 ng) was used as template for each reaction. All reactions were carried out in duplicate with no template control. The PCR conditions were as follows: 95°C for 10 min, followed by 40 cycles of 95°C for 10 se; 60°C for 10 s, and 72°C for 10 s. The mRNA transcript level for each gene was normalized against cyclophilin B.
Data presentation and statistical methods. The kinetic variations of [Ca 2ϩ ]i are presented as percentage changes in 340/380 fluorescence ratios. To quantify the [Ca 2ϩ ]i responses, integrated elevation above baseline (⌬Ca, in arbitrary units) was calculated. Integrated elevation above baseline value (⌬Ins, in ng/8 islets) was used for insulin responses quantitation. All data are presented as means Ϯ SE. Statistical analysis was performed using the unpaired Student's t-test or ANOVA (Fisher test) as appropriate. Differences were considered significant at P Ͻ0.05.
RESULTS

Impaired regulation of cAMP metabolism in diabetic GK/ par islets and its relation to blunted GIIS.
As previously described by us (6), it is remarkable that, in the basal condition (2.8 mmol/l glucose without IBMX), the GK/Par islet cAMP content was significantly increased (by 68%, P Ͻ0.001) compared with those in W islets (Fig. 1B) . However, in the presence of IBMX, W and GK islet cAMP values became identical (Fig. 1B) . Whatever the conditions, the increased cAMP accumulation at low glucose, did not exerted any activation of insulin release in both groups (Fig. 1A) . Under static incubation, 16.7 mM glucose alone stimulated insulin secretion significantly (by 132%, P Ͻ0.001) only in W islets (Fig. 1C) . Under these conditions, we were unable to detect any cAMP accumulation in the GK islet. By contrast, cAMP level significantly increased by 78% (P Ͻ0.05) in W islets (Fig. 1D ).
In agreement with the static incubation experiments (Fig.  1C ), whereas stimulation with 16.7 mM glucose alone triggered a typical response in perifused W islets ( Fig. 2A) Changes in AC, G s ␣, and PDE isoform expressions underly the stronger cAMP elevation in GK/Par islets. To determine the origin of the increased production of cAMP in GK/Par islets, we analyzed the expression of proteins involved in cAMP synthesis (e.g., ACs and PDEs). Using real-time PCR techniques, we found that the relative levels of AC1, AC2, and AC3 mRNA in diabetic GK/Par islets were significantly increased by 26, 130, and 90%, respectively, compared with control W islets (Fig. 4A ). In contrast, the relative level of AC8 mRNA was significantly decreased by 60% in GK/Par islets compared with control W islets. Western blot analysis performed on total islet lysates showed that levels of AC3, AC2, and G s ␣ proteins were increased in GK islets compared with W islets (Fig. 4B ). Quantitative densitometry after normalization with MEK1 protein revealed ϳ160% (P Ͻ 0.05), 100% (P Ͻ 0.05), and 40% (P Ͻ 0.05) increases of these proteins, respectively (not shown). AC8 protein level was decreased in GK compared with W ( Fig. 4B ) by 40% (P Ͻ 0.01) (not shown). Immunofluorescence confocal microscopy was also performed to determine the cellular intensity and localization of G s ␣ protein. Figure 4C shows that G s ␣ labeling of islet cells was increased in GK/Par compared with W islets and that this protein colocalizes with insulin. We also found that the relative levels of PDE-1C and PDE-3B mRNA were significantly decreased by 41 and 15%, respectively, in GK/Par islets compared with W islets (Fig. 4A) . These results may suggest that the underexpression of these PDE isoforms could contribute to increased accumulation of cAMP in the basal state in GK/Par islets. All together, these data indicate that the machinery involved in cAMP production in the basal state is overexpressed and hyperactive in ␤-cells from diabetic GK/Par islets.
Direct pharmacological manipulation of hyperactive islet cAMP production restores GIIS by GK/par islets. We first tested a direct activator of AC on GIIS from GK islets. Figure 5 shows that stimulation of membrane-bound AC activity with forskolin at various concentrations, under static incubation at 16.7 mM glucose, increased [cAMP] i significantly more in GK/Par islets than in W islets (Fig. 5A) . Moreover, incubation with forskolin allowed the restitution of the GIIS in GK/Par islets (Fig. 5B) . Figure 6A shows that [cAMP] i remains significantly increased in GK/Par islets during inhibition of PDE with low to mild concentrations of IBMX and in the presence of 16.7 mM glucose. However, if we consider the relationship between cAMP contents and IBMX concentrations (Fig. 6A) , the lower slope in the GK/Par islets suggests that overall islet PDE activity is decreased in this group. Moreover, incubation with IBMX increased dose dependently but did not fully restore the GIIS by GK/Par islets (Fig. 6B) .
Insulin secretion is less responsive to [cAMP] i in GK/par islets. Data generated by the above forskolin and IBMX protocols give the opportunity to establish the relationship between GIIS rate and intra-islet cAMP accumulation in both normal and diabetic islets ( Fig. 7A and 7B ). Figure 7A shows that, within a range from basal to mildly elevated cAMP concentrations, cAMP-induced amplification of GIIS can be obtained, but cAMP is roughly twice as less efficient in GK/Par islet as in normal W islets. This demonstrates that the GK/Par ␤-cells are to some extent less sensitive to cAMP action. Figure 7B shows that, at the expense of very high cAMP concentrations (roughly 5 times higher than for W islets), maximal cAMP-induced amplification of GIIS is obtainable in GK/Par islets. This demonstrates that the GK/Par ␤-cells are still capable of responding maximally to cAMP despite some degree of cAMP resistance.
cAMP overproduction by GK/par islets can be further enhanced by GLP-1 and is instrumental in GIIS restitution. In islets exposed to 2.8 mmol/l glucose and in the absence of IBMX, GLP-1 induced a significant increase in cAMP levels (by 55%, P Ͻ0.01) in the GK/Par group only (Fig. 8B) . Addition of IBMX potentiated their cAMP accumulation in response to GLP-1 (Fig. 8B) . The presence of IBMX permitted us to reveal an increase of cAMP levels in response to GLP-1 in both groups. Under this last condition, the relative GLP-1-induced cAMP increase was significantly more important in the GK/Par islet compared with W (98 vs. 59%, P Ͻ0.05; Figs. 1B and 8B). In the same static incubation experiments performed at 2.8 mmol/l glucose, GLP-1 was unable to significantly increase insulin release in the GK/Par islets as well as in W islets (Fig. 8A) . The lack of effect of GLP-1 on insulin secretion persisted in the presence of IBMX in both groups (Fig. 8A) .
In islets exposed to 16.7 mmol/l glucose, GLP-1-induced cAMP accumulation was increased in both GK/Par and W islets (Fig. 8D) , but the amplification factor expressed as percent above basal was more important in the GK/Par group, both in the absence (117 vs. 47%, P Ͻ0.001) and in the presence of IBMX (435 vs. 181%, P Ͻ0.001). When expressed as percent above basal value, GLP-1 increased the GIIS more potently in GK/Par islets than in W islets (Figs. 1C and 8C) , both in the absence (69 vs. 44%, P Ͻ0.01) and in the presence of IBMX (334 vs. 91%, P Ͻ0.001). In the presence of IBMX, GLP-1 increased GIIS in the GK/Par islets to an extent similar to that in the W (Fig. 8C) . In perifusion experiments, we also found that GLP-1 potentiated 16.7 mmol/l GIIS in both W and GK/Par islets (Fig. 2, A and C) . Again, the total amount of ] i above baseline (Fig. 3B) . By contrast, GLP-1 did not modify significantly the glucose-activated [Ca 2ϩ ] i pattern in the GK/Par islets (Fig. 2, B and D) , with an unchanged integrated elevation of [Ca 2ϩ ] i above baseline (Fig. 3B) . However, the [Ca 2ϩ ] i elevation was slightly anticipated in both islet groups, with loss of the initial decrease of [Ca 2ϩ ] i in the W islets (Fig. 2, B and D) .
To determine the relationship between the insulinotropic effect of GLP-1 and cAMP overproduction in GK/Par islets, we used a potent inhibitor of membrane-bound AC isoforms, 2=,5=-dideoxyadenosine (dd-Ado). During perifusion of GK/ Par islets with a nonstimulatory glucose concentration (2.8 mM), addition of dd-Ado alone did not alter basal insulin release in GK/Par islets (Fig. 9) . In addition, dd-Ado did not affect the insulin release obtained in response to 16.7 mM glucose alone in GK/Par islets [⌬Ins 0 -20min : 13.8 Ϯ 1.8 (n ϭ 5) vs. 13.5 Ϯ 1.6. (n ϭ 12) ng/8 islets with or without dd-Ado, respectively]. By contrast, in the presence of dd-Ado, GLP-1 potentiation of GIIS became significantly (P Ͻ0.001) blunted (⌬Ins 0 -20min : 6.6 Ϯ 2.3 vs. 76.6 Ϯ 14.9 ng/8 islets; Fig. 9 ). We next used H89, a potent inhibitor of PKA. Inhibition of PKA activity by H89 also blocked GLP-1 potentiation of GIIS (Figs.  2C and 9 ). Together, these data indicate that GLP-1 restores GIIS in diabetic GK/Par islets through the activation of the cAMP/PKA pathway.
GLP-1 activation of cAMP production is also crucial for GIIS recovery in diabetic nSTZ islets. Overexpression of several AC isoforms was also described in nSTZ rat islets (8) , and nSTZ islets also exhibit a phenotype of defective GIIS very similar to that of GK/Par islets (3). Such similarities, despite different diabetes etiologies in these two models of T2D, prompted us to conduct the study here described.
One should mention first that, as in GK/Par islets, the basal cAMP accumulation in nSTZ islets was significantly increased (P Ͻ0.05) compared with W islets. In islets exposed to 2.8 mmol/l glucose and in the absence of IBMX, GLP-1 induced a significant increase in cAMP level (by 39%, P Ͻ0.01) in the nSTZ group only (Fig. 10B) . In W islets, the presence of IBMX permitted us to reveal an increase of cAMP levels in response to GLP-1 that turned out to be similar in the nSTZ and W islets (49 vs. 52% increase; Fig. 10B ). In the same static incubation experiments performed at 2.8 mmol/l glucose, GLP-1 alone was unable to increase insulin release by both types of islets (Fig. 10A) . The lack of significant effect of GLP-1 on insulin secretion in both W and nSTZ islets was not affected by the presence of IBMX (Fig. 10A) .
In response to 16.7 mmol/l glucose alone, cAMP accumulation increased in W islets but not in nSTZ islets (Fig. 10D) . In the presence of 16.7 mmol/l glucose, GLP-1 increased cAMP accumulation in both nSTZ and W islets with a similar amplification factor (Fig. 10D) in the absence as in the pres- ence of IBMX. GLP-1 significantly amplified GIIS in nSTZ islets (Fig. 10C ) both in the absence (90%, P Ͻ0.01) and in the presence of IBMX (125%, P Ͻ0.001). Such GLP-1 amplification was sufficient to obtain a GIIS rate similar to that of the W islets exposed to 16.7 mmol/l glucose alone. The GIIS rate, when expressed in absolute value, remained, however, lower (P Ͻ0.001) in the nSTZ islets than was in the W islets exposed to the same GLP-1/IBMX combination (Fig. 10C) .
DISCUSSION
Our previous studies have suggested that the downregulation of glucose oxidation and subsequent Ca 2ϩ metabolism has a primary role in the loss of insulin secretion by GK/Par rat islets (33) and also in islets from the nSTZ rat model of T2D (32) . A likely result of this decreased metabolism is decreased activation of other intracellular pathways that potentiate insulin secretion in the normal situation. However, it is unclear to what extent these potentiation pathways are really modified, since there are reports that pharmacological activation of either the cAMP-or the Ach-dependent pathway improves in vitro insulin release by GK islets (1, 6) .
Increased cAMP production by GK/par islets. In the present study, we focused on changes in cAMP levels to determine whether alterations in cAMP metabolism are involved in alteration of the insulin secretion by GK/Par islets. Under a low glucose concentration (2.8 mM), we found that basal cAMP content in GK/Par islets was significantly higher, whereas their basal insulin release was not significantly different from W islets. Even in the presence of IBMX or GLP-1, their insulin release did not significantly change despite further enhanced cAMP accumulation in both cases.
The mechanism by which increased levels of cAMP occur in GK/Par islets remains to be understood. The simplest explanation would be an increase in the production of cAMP by AC and/or a decrease in its breakdown by cyclic nucleotide PDEs. The elevated basal levels of cAMP in the GK/Par islets most likely reflects an increase in the production of cAMP because this change was observed in the absence as well as in the presence of the PDE inhibitor IBMX. This interpretation is supported by our previous findings that some AC (AC2 and AC3) and the G␣olf mRNA are more abundant in GK/Par islets than in W islets (8) . In the present paper, based on quantitative RT-PCR and immunolocalization protocols, we now confirm that AC2, AC3, and G s ␣ proteins are indeed overexpressed in GK/Par ␤-cells. However, this is not a general phenomenon, since the AC8 isoform was underexpressed. We also show that forskolin, which is known to directly stimulate all membrane-bound AC isoforms (19) , induced an exaggerated cAMP generation in GK/Par islets compared with W islets regardless the concentration used. This clearly indicates that the AC isoforms overexpressed in the GK/Par islet are functional. Similar overexpression of AC (including also the AC1 and AC8 isoforms) and G s have been reported in islets from GK/Sto rats (12, 29) . However, there are discrepancies between cAMP data reported from these two GK rat lines, which render hazardous any extrapolation from one model to the other: even if forskolin and PACAP (pituitary adenylyl cyclase-activating polypeptide) also induced an exaggerated increase in cAMP generation irrespective of glucose concentration (1, 30) , no elevation of islet cAMP under basal condition (low glucose) was detected in the GK/Sto (13) in contrast to the GK/Par islets. In the GK/Sto rat, it has been shown that increased AC3 is due to functional mutations in the promoter region of the Ac3 gene (2). We do not retain this hypothesis in the GK/Par islet, since we found that the expression (mRNA) of AC2 and AC3, and of G␣S, and G␣olf, are not increased in the prediabetic islet (before installation of basal hyperglycemia) (21) .
Our data also show that overall islet PDE activity is decreased in the GK/Par islets, since the relative increase of cAMP accumulation in response to various IBMX concentrations was less efficient in these islets compared with W islets. As shown by our quantitative RT-PCR experiments, PDE-1C and PDE-3B, two PDE isoforms that regulate the cAMP pool responsible for modulating insulin release (14, 15) , are indeed underexpressed in the GK/Par islets. Since overexpression of constitutively mutant of G s ␣ in ␤-cells of transgenic mice was reported to be associated with compensatory increased activity of cAMP-PDE (24), our observation of decreased expression of PDE isoforms in the GK/Par islet may look paradoxical. One possible explanation for this discrepancy is that G s ␣, while overexpressed, could be functionally altered in GK/Par islets due to chronic exposure in vivo to high plasma glucose concentration. Indeed, Phan et al. have demonstrated that prolonged exposure of ␤-cells to high glucose might induce intracytoplasmic sequestration of G␣olf and G s ␣ proteins in a nonfunctional state (28) . To summarize, for the multiple reasons reported above, the cAMP turnover is greatly altered in the GK/Par ␤-cell, thereby allowing strong elevations of cAMP accumulation both at basal unstimulated condition and during AC activation.
Our results in W islets agree with previous reports demonstrating such effect of glucose on cAMP accumulation in nondiabetic ␤-cells (25) . Production of cAMP in glucosestimulated ␤-cells has been attributed to Ca 2ϩ influx and Ca 2ϩ /calmodulin activation of Ca 2ϩ -sensitive isoforms of AC (38) . That Ca 2ϩ plays a central role in stimulating AC is clearly demonstrated by the simultaneous imaging of Ca 2ϩ and cAMP in MIN6 cells stimulated with 20 mmol/l glucose and following removal of extracellular Ca 2ϩ or application of an inhibitor of voltage-dependent Ca ϩ channels (22) . Concerning the GK/ Par ␤-cells, our observations suggest that their cAMP production is insensitive to glucose. With regard to the Ca 2ϩ /calmodulin-sensitive activation of AC by glucose in the nondiabetic islets, the lack of glucose-induced cAMP accumulation in diabetic GK islets could be related to the inability of glucose to raise [Ca 2ϩ ] i sufficiently. Reduced effectiveness of cAMP in GK/par islets. The role of cAMP as an amplifying factor of GIIS is well established (35, 36) . The low first-and second-phase responses to glucose in the GK/Par islets could also be related to a reduced ␤-cell capacity to respond to cAMP. Here, we show that this option is clearly supported, as we found a major qualitative difference in effectiveness of cAMP between the GK/Par and W ␤-cells. cAMP amplification of GIIS by W islets reached maximal at 3-4 fmol cAMP/ng islet DNA, with no additional release at islet cAMP level of 5 fmol cAMP/ng islet DNA. By contrast, GK/Par islets released only one-half of the amount of insulin than W at the range 3-to 4-fmol cAMP level, continued to secrete additional insulin within the range of 5-15 fmol/ng islet DNA, finally achieving a maximum no longer different from W secretion at the 15-to 40-fmol cAMP level. Therefore, the important new message is that GK/Par islets differ from normal W islets in that their insulin release apparatus appears less sensitive to a given level of cAMP. Differences in sensitivity to cAMP at the level of intracellular Ca 2ϩ , PKA, and target phsophorylation sites in the insulin exocytotic pathway could account for the reduced effectiveness of cAMP in the GK/Par islet and should be considered.
GLP1-induced restitution of GIIS in GK/par islets.
Since our data also demonstrated that GK/Par ␤-cells are still capable of responding maximally to cAMP despite some degree of cAMP resistance, we studied the effect of GLP-1 on GIIS in freshly isolated GK/Par islets. We found that GLP-1 was able to restore the insulin-secretory glucose competence of the GK/Par ␤-cell in a way such that GIIS became indistinguishable from that of normal W islets. Furthermore, we report that GLP-1 also normalized GIIS in islets from nSTZ rats (another recognized model of rat diabetes with glucose-unresponsive ␤-cells) (3, 4) . This suggests that restoration by GLP-1 of glucose responsiveness in the diabetic ␤-cell is not restricted to the GK model but is probably a more generalized mechanism. Because the mechanism underlying the insulinotropic action of GLP-1 in an in vitro model of unresponsive ␤-cells (dispersed rat ␤-cells) has been shown to involve activation of AC with resultant stimulation of cAMP production (18), we investigated the effect of GLP-1 stimulation on cAMP production in GK/ Par and W rats. At variance with their lack of cAMP response to high glucose, islets from diabetic GK/Par rats were able to amplify their cAMP content in response to GLP-1 in the presence of 16.7 mM glucose. Importantly, their strong and even exaggerated cAMP production (as compared with W response) was associated with a strong insulin release. This observation is germane to our recent report that Ach is also able to restore glucose competence in the GK/Par ␤-cells through activation of the cAMP/PKA pathway (6) . In the present work, we also found (data not shown) that Ach did not further enhance either insulin secretion or cAMP accumulation induced by GLP-1. This confirms the view that both GLP-1 and Ach are able to activate the cAMP/PKA pathway in the GK/Par ␤-cells.
Our data suggest that GLP-1-stimulated cAMP generation is instrumental in the GLP-1-triggered insulin release at high glucose by GK/Par islets, since insulin release became no longer reactive to GLP-1 when AC isoforms were acutely blocked by the AC blocker dd-Ado. This also indicates that GLP-1, at pharmacological dosage, is able to generate within the GK/Par ␤-cell cAMP levels high enough to cope for the reduced effectiveness of cAMP. What are the mechanisms to account for the enhanced capacity of GLP-1 to generate cAMP and activate insulin secretion in the GK/Par islet? The possibility that the GLP-1-receptor number may be increased does not hold true, since by using RT-PCR analysis we found that GLP-1-R mRNA was significantly decreased (P Ͻ 0.001) in GK/Par islets compared with W islets [GK 0.508 Ϯ 0.021 (n ϭ 4) vs. W 0.847 Ϯ 0.027 (n ϭ 4)] (normalized against cyclophilin B mRNA). It has been recently shown that alterations of glucose, lipid, and energy metabolism as well as ATP production are not involved in the mechanisms whereby GLP-1 augments GIIS in the normal rat ␤-cell (27) . Moreover, forskolin had no effect on glucose utilization by GK/Sto islets (1). Therefore, it is highly improbable that the GLP-1-induced GIIS recovery in the GK/Par ␤-cell is due to restitution of normal glucose metabolism/Ca 2ϩ /cAMP coupling. Probably of greater relevance is the well-established ability of GLP-1 to directly stimulate cAMP production in the normal ␤-cell (35) , an effect that is clearly enhanced in the GK/Par islet. Since there are proofs for an enhanced expression of the stimulatory G s proteins/ACs axis in GK/Par ␤-cells, the simplest explanation is that it relates, at least in part, to an increased GLP-1 receptor coupling to ACs and to increased activity of some ACs.
How, then, does increased cAMP generation participate in the GLP-1-reactivated insulin secretion in the GK/Par islet? In the normal ␤-cell, a number of reports have stressed the importance of both PKA-dependent phosphorylation (5, 17) and PKA-independent activation (39) . Exocytosis has been reported to be activated directly by cAMP (11, 37) , and interactions of the cAMP-binding protein cAMP-GEFII/Epac2 with SUR1 and Rim2 have been identified (20, 26) . It is unknown so far whether the cAMP-dependent PKA-independent pathway may also participate in the GLP-1-induced insulin release in the GK/Par ␤-cells. Our observation that the PKA inhibitor H89 markedly blunted the GLP-1-potentiation of GIIS by the GK/Par islet argues against a role of the cAMPdependent PKA-independent pathway. Holz et al. (18) have demonstrated a synergistic depolarization of non diabetic ␤-cells by glucose and GLP-1, PKA-dependent phosphorylation, and closure of the K ATP channels. However, because we were unable to detect any elevation of the integrated [Ca 2ϩ ] i value in response to glucose ϩ GLP-1 compared with glucose alone, we postulate that such indirect (PKA-dependent) effect of GLP-1 on membrane depolarization is not of major importance for potentiation of GIIS. More relevant to our data is the report by Gromada et al. (10) that the main action of GLP-1 on exocytosis is exerted distally to the elevation of [Ca 2ϩ ] i in mouse ␤-cells. Finally, since the GLP-1-reactivated insulin secretion by the GK/Par ␤-cell arises mostly from increased action of coupling factors and not from increased energy metabolism, one may postulate that its basal glucose utilization rate is sufficient to cover the energy cost of the processes activated by GLP-1 such as the ATPases, the release of the insulin vesicles from the readily releasable pool, and the ATP-dependent refilling of this pool. This observation is also consistent with the recent report that insulin secretion is a minor energy consuming process in the normal ␤-cell (27) .
